36 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp07889 | H-58 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 0.62 ± 0.12 μM |
| dbacp07890 | H-58 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 1.29 ± 0.08 μM |
| dbacp07891 | H-58 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 2.13 ± 0.07 μM |
| dbacp07892 | H-57 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 0.62 ± 0.12 μM |
| dbacp07893 | H-57 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 1.29 ± 0.08 μM |
| dbacp07894 | H-57 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 2.13 ± 0.07 μM |
| dbacp07895 | H-18 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 0.89 ± 0.21 μM |
| dbacp07896 | H-18 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 1.11 ± 0.21 μM |
| dbacp07897 | H-18 | IKLSKKTKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 1.61 ± 0.21 μM |
| dbacp07898 | H-21 | IKLSKS5TKKS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 3.26 ± 0.36 μM |
| dbacp07899 | H-21 | IKLSKS5TKKS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 3.05 ± 0.21 μM |
| dbacp07900 | H-21 | IKLSKS5TKKS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 1.50 ± 0.28 μM |
| dbacp07901 | H-20 | IKLSPS5TKKS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 2.10 ± 0.32 μM |
| dbacp07902 | H-20 | IKLSPS5TKKS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 2.63 ± 0.35 μM |
| dbacp07903 | H-20 | IKLSPS5TKKS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 4.93 ± 0.53 μM |
| dbacp07904 | H-19 | IKLSKETKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 1.00 ± 0.36 μM |
| dbacp07905 | H-19 | IKLSKETKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 1.78 ± 0.35 μM |
| dbacp07906 | H-19 | IKLSKETKKNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 1.64 ± 0.36 μM |
| dbacp07907 | H-17 | IKLSKS5TKKS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 0.96 ± 0.33 μM |
| dbacp07908 | H-17 | IKLSKS5TKKS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 1.49 ± 0.45 μM |
| dbacp07909 | H-17 | IKLSKS5TKKS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 1.64 ± 0.47 μM |
| dbacp07910 | H-16 | IKLSPS5TKKS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 1.85 ± 0.31 μM |
| dbacp07911 | H-16 | IKLSPS5TKKS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 2.65 ± 0.35 μM |
| dbacp07912 | H-16 | IKLSPS5TKKS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 3.14 ± 0.46 μM |
| dbacp07913 | H-15 | IKLSKS5TKDS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 2.26 ± 0.24 μM |
| dbacp07914 | H-15 | IKLSKS5TKDS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 2.95 ± 0.25 μM |
| dbacp07915 | H-15 | IKLSKS5TKDS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 2.20 ± 0.27 μM |
| dbacp07916 | H-10 | IKLSPS5TKDS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 3.59 ± 0.12 μM |
| dbacp07917 | H-10 | IKLSPS5TKDS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 3.51 ± 0.37 μM |
| dbacp07918 | H-10 | IKLSPS5TKDS5LKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 1.50 ± 0.21 μM |
| dbacp07919 | H-5 | IKLSPETKDNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 7.35 ± 0.22 μM |
| dbacp07920 | H-5 | IKLSPETKDNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 4.16 ± 0.21 μM |
| dbacp07921 | H-5 | IKLSPETKDNLKKVLKGS5IKGS5IAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 2.82 ± 0.23 μM |
| dbacp07922 | H-2 | IKLSPS5TKDS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | A-549 | Lung Cancer | IC50 = 4.26 ± 0.52 μM |
| dbacp07923 | H-2 | IKLSPS5TKDS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HCT-116 | Colon Cancer | IC50 = 3.54 ± 0.72 μM |
| dbacp07924 | H-2 | IKLSPS5TKDS5LKKVLKGAIKGAIAVAKMV | Synthetic | Cell entry, DNA damage, apoptosis. | MTT assay | HepG-2 | Liver Cancer | IC50 = 1.60 ± 0.24 μM |